Subscribe to stay informed!
After failing to convince the Food and Drug Administration that there is no need for additional testing for its lead new drug candidate, Malvern-based…
Malvern-based Galera Therapeutics is expecting to raise $30 million from a direct stock offering by the end of the week, writes John George for…
At the start of the week, the stock market entered bear territory for the first time since 2020, further pushing down many local companies that…
Malvern-based Galera Therapeutics’ stock fell by more than 70 percent after the biopharmaceutical firm announced that its cancer drug candidate did not meet its…
Malvern-based Galera Therapeutics recently triggered a $37.5 million payment by completing enrollment for a late-stage study of Avasopasem. John George reported on…
Malvern-based Galera Therapeutics is developing solutions that are reducing the negative side effects of radiation therapy and helping to improve treatment and outcomes for…
At $12 a share, Malvern-based Galera Therapeutics raised $60 million in its initial public offering and is now trading under the GRTX symbol on…
Fox Rothschild
The firm has announced that its Emerging Companies & Venture Capital practice group has been recognized in the 2018 Chambers USA guide in…
Valley Forge Educational Services
The Malvern-based Valley Forge Educational Services, which offers a continuum of school-year and summer educational programs and integrated clinical…
Before we send you to this site, please subscribe to our daily newsletter.